SpainSpain

Almirall comes out on top in spat

09.08.2011

Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes, the European Commission had to help prod the process along.
The row between Almirall and Boeh­ringer began in 2003, when the German firm filed patent applications for new treatments of chronic obstructive pulmonary disease (CODP). These applications related to combinations of three broad categories of active substances for treating COPD, along with a new active substance that had been discovered by the Spanish biopharmaceutical company. Almirall duly objected, stating that the patents were “unmeritous”, and if granted would hinder the market entry of its own combination medicines. In 2007, the EU Commission opened an investigation.
Three years later, it suggested in 2010 that the rivals find a mutually acceptable solution to their dispute that would also conform to EU antitrust rules. In early July, the two finally reached a deal when Boehringer agreed to remove the alleged ‘blocking’ positions. With the agreement, all pending litigation is to come to an end, and the EU will drop its investigation. Almirall now has the all-clear to launch its own combination drugs following marketing authorisation. The Spanish company did not disclose exactly which substances are being considered longer term.
Just weeks after the deal however, Almirall submitted a marketing authorisation application to the EMA for aclidinium bromide, an inhaled muscarinic antagonist for the treatment of COPD. Boehringer is the market leader in the treatment of the disease. Its blockbuster drug Spiriva (tiotropium) achieved worldwide turn­over totalling nearly EUR3bn in 2010.

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

SpainSpain

01.10.2011

Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...

SpainSpain

29.09.2011

Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...

SpainSpain

23.09.2011

Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain

18.08.2011

Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...

SpainSpain

13.06.2011

Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...

SpainSpain

11.06.2011

Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...

SpainSpain

06.02.2011

Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

SpainSpain

06.02.2011

Madrid – Nowhere in the world, is the concentration of GM-sceptics higher than it is in Europe, but their reign is not supreme. On the south-western tip of the continent, Spain stands out for its “science-based agricultural...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/1/article/almirall-comes-out-on-top-in-spat.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%

FLOP

  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%

TOP

  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014


Current issue

All issues

Product of the week

Products